About Carbonyl reductase [NADPH] 1
Carbonyl reductase [NADPH] 1 (CBR1) is a protein
from Homo sapiens identified by UniProt accession
P16152, 277 residues long.
MolForge cross-references it against 0 known binders and
120 disease associations.
Target properties
| Protein name | Carbonyl reductase [NADPH] 1 |
|---|
| UniProt accession | P16152 |
|---|
| Gene | CBR1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 277 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (1)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (120)
Diseases linked to this target (Open Targets).
- neurodegenerative disease · score 0.37
- insulin like growth factor measurement · score 0.26
- IGF-1 measurement · score 0.23
- C-reactive protein measurement · score 0.22
- blood protein measurement · score 0.20
- head and neck squamous cell carcinoma · score 0.09
- major depressive disorder · score 0.08
- oral squamous cell carcinoma · score 0.07
- heel bone mineral density · score 0.06
- Obesity · score 0.06
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P16152-F1 | alphafold | PREDICTED | 97.77 | — |
Amino-acid sequence (277 residues)
MSSGIHVALV TGGNKGIGLA IVRDLCRLFS GDVVLTARDV TRGQAAVQQL QAEGLSPRFH QLDIDDLQSI RALRDFLRKE YGGLDVLVNN AGIAFKVADP TPFHIQAEVT MKTNFFGTRD VCTELLPLIK PQGRVVNVSS IMSVRALKSC SPELQQKFRS ETITEEELVG LMNKFVEDTK KGVHQKEGWP SSAYGVTKIG VTVLSRIHAR KLSEQRKGDK ILLNACCPGW VRTDMAGPKA TKSPEEGAET PVYLALLPPD AEGPHGQFVS EKRVEQW
Explore Carbonyl reductase [NADPH] 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets